Perspective - (2025) Volume 14, Issue 5
Received: 01-Sep-2025, Manuscript No. jmmd-26-184703;
Editor assigned: 03-Sep-2025, Pre QC No. P-184703;
Reviewed: 07-Sep-2025, QC No. Q-184703;
Revised: 22-Sep-2025, Manuscript No. R-184703;
Published:
29-Sep-2025
, DOI: 10.37421/2161-0703.2025.14.547
Citation: Hassan, Noura. ”Differentiating Dengue And Chikungunya: A Diagnostic Guide.” J Med Microb Diagn 14 (2025):547.
Copyright: © 2025 Hassan N. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
The clinical presentation of dengue and chikungunya often exhibits significant overlap, presenting a substantial challenge for differential diagnosis in endemic and co-endemic regions [1].
Both viral infections are arthropod-borne and share common symptoms such as fever, rash, and myalgia, necessitating a thorough understanding of their distinct features and diagnostic approaches [2].
Dengue, a mosquito-borne viral disease, can manifest with a wide spectrum of illness, ranging from asymptomatic infections to severe dengue, including dengue hemorrhagic fever and dengue shock syndrome [3].
Chikungunya virus infection, on the other hand, is characteristically associated with acute onset of fever and severe, often debilitating, joint pain that can persist for months or even years [4].
The integration of molecular and serological diagnostic tools is paramount for the timely and accurate identification of these infections, especially during outbreaks where rapid confirmation is crucial for effective patient management and public health response [5].
Understanding the temporal dynamics of viral shedding and antibody production is essential for selecting the most appropriate diagnostic method at different stages of infection [1].
Serological diagnostics, particularly the detection of IgM and IgG antibodies, play a critical role in confirming past or recent infections, providing insights into immune responses and aiding in epidemiological surveillance [6].
The immune response, characterized by the kinetics of antibody production, guides the interpretation of serological tests, with IgM typically appearing early and IgG indicating a later or past infection [6].
Early diagnosis of dengue infection is of utmost importance for effective patient management, with NS1 antigen detection and RT-PCR being key molecular methods for identifying the virus in the initial stages of illness [7].
Similarly, chikungunya virus infection requires prompt diagnosis using both serological assays and molecular methods to confirm infection and manage its diverse clinical manifestations, including potential neurological and cardiac complications [8].
The diagnostic challenges are amplified in cases of co-infection, where overlapping clinical symptoms can obscure the diagnosis, making multiplex molecular assays a valuable tool for simultaneous detection of both viruses [9].
Current diagnostic strategies for dengue and chikungunya encompass a range of techniques, from rapid diagnostic tests (RDTs) and enzyme-linked immunosorbent assays (ELISAs) to real-time reverse transcription polymerase chain reaction (RT-PCR), each with its own advantages and limitations in different settings [10].
Distinguishing between dengue and chikungunya relies heavily on specific laboratory findings, as their clinical symptoms often overlap, making differential diagnosis challenging [1].
While both cause fever and rash, chikungunya is more frequently associated with severe arthralgia, whereas dengue can present with more pronounced hemorrhagic manifestations [2].
The diagnostic utility of IgM and IgG antibody detection, alongside viral RNA detection via RT-PCR, is discussed for accurate case confirmation [2].
This review emphasizes the evolving clinical spectrum of dengue, from asymptomatic infections to severe dengue, including dengue hemorrhagic fever and dengue shock syndrome, and details the role of NS1 antigen detection for early diagnosis in the acute phase, followed by seroconversion (IgM and IgG) in later stages [3].
The challenges in diagnosing co-infections with chikungunya are also addressed [3].
Chikungunya virus infection often presents with acute onset of fever and severe, often debilitating, joint pain that can persist for months or even years, and laboratory diagnosis typically involves detecting viral RNA by RT-PCR during the viremic phase, followed by serological tests for IgM and IgG antibodies [4].
This paper discusses the nuances of interpreting these diagnostic results, particularly in endemic areas [4].
The integration of molecular and serological diagnostics is crucial for managing outbreaks of dengue and chikungunya, with RT-PCR offering high sensitivity and specificity for early viral detection, while rapid diagnostic tests provide point-of-care results for antibody detection [5].
This study examines the performance of various diagnostic platforms in confirming infections in a co-endemic region [5].
Understanding the immune response to dengue and chikungunya is key to interpreting serological diagnostics, with IgM antibodies typically appearing within a week of symptom onset and persisting for several months, while IgG antibodies indicate a past infection or vaccination [6].
This article details the kinetics of antibody production and their utility in epidemiological surveillance and clinical management [6].
The clinical presentation of dengue can range from mild, flu-like symptoms to severe, life-threatening manifestations such as dengue hemorrhagic fever and dengue shock syndrome, and early diagnosis is critical for effective patient management [7].
This study focuses on the performance of NS1 antigen detection and RT-PCR in the initial stages of dengue infection [7].
Chikungunya virus infection is characterized by acute fever and severe polyarthralgia, often leading to chronic joint pain, and this article examines the spectrum of clinical manifestations, from typical acute presentations to less common neurological and cardiac complications [8].
It also reviews the laboratory diagnostic tools, including serological assays and molecular methods, for confirming infection [8].
Co-infection with dengue and chikungunya viruses presents diagnostic challenges due to overlapping clinical symptoms, and this study investigates the utility of multiplex RT-PCR assays for simultaneous detection of both viruses, offering a rapid and efficient diagnostic approach during outbreaks [9].
The importance of accurate identification for appropriate clinical management and public health response is emphasized [9].
The timely and accurate laboratory diagnosis of dengue and chikungunya is essential for patient management, outbreak control, and surveillance, and this paper provides an overview of current diagnostic techniques, including rapid diagnostic tests (RDTs), enzyme-linked immunosorbent assays (ELISAs), and real-time reverse transcription polymerase chain reaction (RT-PCR) [10].
It discusses the advantages and limitations of each method in different clinical and epidemiological settings [10].
Dengue and chikungunya present overlapping clinical symptoms, making differential diagnosis difficult. Key laboratory diagnostic methods include serological assays (ELISA, RDTs) for antigen and antibody detection, and molecular techniques (RT-PCR) for early viral detection. Understanding the temporal window for each diagnostic method is crucial for accurate and timely diagnosis. While both cause fever and rash, chikungunya is more associated with severe joint pain, and dengue with hemorrhagic manifestations. NS1 antigen detection and RT-PCR are vital for early dengue diagnosis, while seroconversion (IgM, IgG) indicates later stages. Chikungunya diagnosis often involves RT-PCR during viremia and subsequent serological tests. Co-infections require advanced methods like multiplex RT-PCR. The immune response, particularly antibody kinetics (IgM, IgG), aids in interpreting serological results for surveillance and management. Various diagnostic platforms, including RDTs and ELISAs, are evaluated for their performance.
None
None
Medical Microbiology & Diagnosis received 14 citations as per Google Scholar report
